- 13,567 bottles of 25 mg chlorthalidone tablets have been recalled after failing lab checks, in line with the FDA.
- It’s the producer’s second recall of the tablets this yr, all with the identical expiration date.
- Collectively, the 2 Class II recollects cowl 25,027 bottles, in line with FDA enforcement reviews.
The report lists the explanation for the recall as “Failed Dissolution Specs.” Which means the tablets failed a check that measures how the drugs is launched from the tablet,
“Chlorthalidone is a diuretic, or ‘water tablet,’ generally used to treat high blood pressure and reduce excess fluid retention within the physique,” Cheng-Han Chen, MD, a board licensed interventional heart specialist at MemorialCare Saddleback Medical Heart in Laguna Hills, CA, advised Healthline.
That is the second time this yr Inventia has recalled its 25 mg chlorthalidone tablets.
The first recall was initiated on June 5 and coated 11,460 bottles. Each have been for a similar motive: failed dissolution specs, in line with FDA enforcement reviews.
Collectively, the June and September recollects cowl 25,027 bottles.
The FDA categorized each recollects as
The 2 recollects cowl three batches of the chlorthalidone tablets, USP, 25 mg, in line with the FDA enforcement reviews. All three expire in April 2027.
The 25 mg tablets are mild yellow, spherical and flat, with “103” stamped on one aspect and nothing on the opposite, according to the drug label.
September 2026 recall (recall quantity D-0852-2026)
Recall initiated on September 3, 2026; 13,567 bottles affected.
- Batch: RISA24002
- 100-tablet bottles
- NDC 64980-599-01
June 2026 recall (recall quantity D-0610-2026)
Recall initiated on June 5, 2026; 11,460 bottles affected.
- Batch RISA24001
- 100-tablet bottles
- NDC 64980-599-01
- Batch RISB24002:
- 1,000-tablet bottles
- NDC 64980-599-10
Sufferers whose provide is a part of the recall “ought to contact their pharmacy to debate acquiring a substitute and ask whether or not they need to proceed taking the remedy within the meantime,” Chen stated.
For Class II recollects, individuals can typically preserve taking the drugs except the recalling firm provides different directions,
In some instances, stopping a medicine could also be extra dangerous than persevering with to take the recalled medication, the company stated.
In case you’re involved that your remedy has been recalled, right here’s what you are able to do:
- Name the pharmacy the place you final refilled your prescription.
- Ask for the producer, NDC, and batch quantity on file.
- Examine these towards the recall lists above.
A Class II recall means utilizing the drug might trigger non permanent well being issues, however the likelihood of great hurt is unlikely,
“The voluntary recollects cited are categorized as Class II, on the retail degree,” an FDA Spokesperson advised Healthline.
A retail-level recall means the corporate is “eradicating the product from retail shops and pharmacy cabinets,” Ileana Elder, a department chief within the FDA’s Workplace of Compliance, stated in an
Healthline reached out to the businesses for extra details about the September recall, however had not heard again by the point of publication. The FDA referred additional inquiries to the businesses
Nonetheless, based mostly on a preliminary evaluation of the batches recalled in June, Rising Pharma Holdings, a distributor of one of many recalled tons, stated that “no affect on affected person well being and security is anticipated.”
“If a medicine doesn’t dissolve on the anticipated charge, it is probably not absorbed by the physique as meant,” Chen stated. “This may scale back the quantity of remedy that reaches the bloodstream and doubtlessly lower its effectiveness.”
A failed consequence means the batch didn’t meet the discharge normal set for that product,
Producers suggest and justify these requirements, and regulators approve them as a part of drug approval, in line with the identical steering.
In the USA, the official requirements keep the identical from the time a drug is launched till it expires, the steering stated.
The September FDA enforcement report doesn’t say how the recalled tablets failed. A discover from Rising Pharma Holdings in regards to the June recall gives extra particulars.
Rising discovered two issues on the 18-month mark of ongoing high quality testing of its 25 mg tablets, the corporate stated in a discover posted by the California State Board of Pharmacy:
- The tablets contained much less chlorthalidone than the permitted minimal: 91.5% of the labeled quantity, when the minimal is 92%.
- On common, 78% of the remedy dissolved throughout the check. The usual requires not less than 80%.
In accordance with the drug label, chlorthalidone treats:
The label recommends that most individuals with hypertension begin with one 25 mg dose per day. That’s the power concerned in each 2026 recollects.
